GlassScriptPhysician profile
Bradley J Runyon
NPI 1013156124
$867.48
in general payments reported to CMS, 2019-2025
19 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.93 · 2020: $14.05 · 2021: $109 · 2022: $249 · 2023: $111 · 2024: $128 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $418.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $135.31 | 2022 | |
| Alimera Sciences, INC. | $96.51 | 2019-2024 | Iluvien, Yutiq |
| Alcon Vision LLC | $93.96 | 2021 | |
| Ani Pharmaceuticals, INC. | $87.80 | 2025 | Iluvien |
| Allergan, INC. | $56.52 | 2022 | |
| Amgen INC. | $56.20 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $53.24 | 2020-2023 | Cequa |
| Rayner Intraocular Lenses Limited | $48.89 | 2023 | Rayone Aspheric, Omidria, Rayone Emv |
| Bausch & Lomb Americas INC. | $33.52 | 2023-2024 | Miebo, Vyzulta |
| Horizon Therapeutics Plc | $32.41 | 2022-2023 | Tepezza |
| Abbvie INC. | $26.14 | 2025 | |
| Mallinckrodt Hospital Products INC. | $25.55 | 2024 | Acthar |
| Dompe US, INC. | $24.85 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.07 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $16.33 | 2024 | Xdemvy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $15.16 | 2021 | |
| Bausch Health US, LLC | $14.96 | 2019 | |
| Shire North American Group INC | $14.62 | 2019 | |
| Oyster Point Pharma, INC. | $14.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Runyon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.